Education
About Us
Working with TipRanks
Follow Us
Oncolytics Biotech (TSE:ONC)
TSX:ONC
Top Page
Oncolytics Biotech
(TSX:ONC)
44Neutral
Positive Factors
Clinical Trial Success
Positive final results from the BRACELET-1 trial showed a significant improvement in median overall survival for patients with metastatic breast cancer when treated with pelareorep plus chemotherapy.
Regulatory Progress
Oncolytics Biotech is planning to launch a P2 study in breast cancer, with the intent of seeking accelerated approval, following positive feedback from the FDA.
Negative Factors
Financial Concerns
Oncolytics Biotech is expected to need to raise capital soon to fund its programs, which may lead to potential dilution and has resulted in the lowering of the 12-month price target.
Oncolytics Biotech (ONC) vs. S&P 500 (SPY)
Market Cap
$77.35M
Dividend YieldN/A
Average Volume (3M)121.04K
Price to Earnings (P/E)―
Beta (1Y)0.09
Revenue GrowthN/A
EPS Growth27.78%
CountryCA
Employees27
SectorHealthcare
Sector Strength78
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.41
Shares Outstanding86,421,590
10 Day Avg. Volume130,589
30 Day Avg. Volume121,040
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)6.80
P/FCF Ratio6.80
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
C$5.52Price Target Upside512.78% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
Oncolytics Biotech Business Overview & Revenue Model
Company DescriptionOncolytics Biotech Inc. is a biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics. The company's flagship product, pelareorep, is a proprietary reovirus-based immuno-oncology therapy designed to target and destroy cancer cells, while also stimulating an anti-tumor immune response. Oncolytics Biotech operates primarily within the biotechnology and pharmaceutical sectors, leveraging cutting-edge research and clinical trials to advance its therapeutic candidates through the regulatory pipeline.
How the Company Makes MoneyOncolytics Biotech generates revenue through strategic partnerships and collaborations with larger pharmaceutical companies for the development and commercialization of its therapeutic candidates. These partnerships may include milestone payments, licensing fees, and royalties on sales if their products receive regulatory approval and reach the market. Additionally, the company may secure funding from grants and governmental support for its research and clinical development programs. Revenue generation is closely tied to the successful progression of its clinical trials and the eventual approval and commercialization of its core product, pelareorep.
Oncolytics Biotech Financial Statement Overview
Summary
Oncolytics Biotech's financial performance is characterized by consistent losses and no revenue generation, typical for early-stage biotech firms. The negative cash flow and high liabilities are mitigated by a stable equity position but necessitate external financing.Income Statement
Oncolytics Biotech shows consistent losses with no revenue generation, which is typical for early-stage biotech firms as they focus on R&D. The EBIT and net income margins are negative, indicating high operational costs relative to nonexistent revenue.20
Very Negative
Balance Sheet
The company has a high level of liabilities compared to equity, but maintains a positive equity position. The debt-to-equity ratio is moderate, and the equity ratio is stable, reflecting a cautious approach to leveraging despite the high-risk nature of the industry.35
Negative
Cash Flow
The company experiences negative operating and free cash flow, which is concerning but expected as it develops products. The cash burn is high, but recent financing activities have alleviated some cash pressure.25
Negative
| Breakdown | |||||
| TTM | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | Gross Profit |
| -328.00K | -403.00K | -392.00K | -452.06K | -446.19K | -485.57K | EBIT |
| -35.39M | -33.79M | -28.57M | -26.23M | -25.46M | -20.69M | EBITDA |
| -35.21M | -33.71M | -26.83M | -25.80M | -25.37M | -20.02M | Net Income Common Stockholders |
| -27.64M | -27.75M | -24.84M | -26.30M | -19.55M | -45.55M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 13.70M | 34.91M | 32.14M | 41.26M | 31.22M | 14.15M | Total Assets |
| 14.87M | 38.82M | 37.33M | 45.88M | 34.35M | 19.66M | Total Debt |
| 0.00 | 423.00K | 373.00K | 654.75K | 402.06K | 506.27K | Net Debt |
| -13.70M | -34.49M | -11.29M | -40.61M | -30.82M | -13.64M | Total Liabilities |
| 8.67M | 11.26M | 10.83M | 9.78M | 9.59M | 19.77M | Stockholders Equity |
| 6.20M | 27.56M | 26.50M | 36.10M | 24.75M | -107.89K |
| Cash Flow | Free Cash Flow | ||||
| -18.51M | -28.46M | -23.41M | -22.72M | -22.10M | -19.92M | Operating Cash Flow |
| -18.43M | -28.45M | -23.36M | -22.43M | -22.07M | -19.91M | Investing Cash Flow |
| -81.16K | 20.22M | -20.40M | -285.95K | -29.30K | -10.90K | Financing Cash Flow |
| 5.04M | 31.99M | 12.21M | 33.02M | 39.77M | 21.02M |
Oncolytics Biotech Technical Analysis
Negative
0.90
Price Trends
1.12
Negative
1.27
Negative
1.33
Negative
Market Momentum
-0.04
Positive
35.90
Neutral
30.95
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:ONC, the sentiment is Negative. The current price of 0.9 is below the 20-day moving average (MA) of 1.02, below the 50-day MA of 1.12, and below the 200-day MA of 1.33, indicating a bearish trend. The MACD of -0.04 indicates Positive momentum. The RSI at 35.90 is Neutral, neither overbought nor oversold. The STOCH value of 30.95 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:ONC.
Oncolytics Biotech Risk Analysis
Oncolytics Biotech disclosed 65 risk factors in its most recent earnings report. Oncolytics Biotech reported the most risks in the “Tech & Innovation” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Oncolytics Biotech Peers Comparison
Overall Rating
UnderperformOutperform
Sector (49)
Financial Indicators
Performance Comparison
TSE:ONC
Oncolytics Biotech
0.90
-0.51
-36.52%
TSE:CRDL
Cardiol Therapeutics
1.55
-0.41
-20.92%
Oncolytics Biotech Earnings Call Summary
Earnings Call Date: Mar 7, 2025 | % Change Since: -16.67% | Next Earnings Date: May 2, 2025
Earnings Call Sentiment Neutral
The call highlighted significant clinical advancements and promising business development efforts, particularly in breast and gastrointestinal cancers. However, financial challenges, leadership transitions, and regulatory uncertainties pose notable concerns.Highlights
BRACELET-1 Breast Cancer Study Exceeds Expectations
The final data from the BRACELET-1 breast cancer study not only met but exceeded expectations, showing a marked statistically significant near doubling of median overall survival in HR-positive HER2-negative metastatic breast cancer.
Positive Results in Gastrointestinal Tumors
Initial safety and efficacy data in both pancreatic and anal cancers are positive. A 33% objective response rate was reported from the goblet cohort four in relapsed anal cancer, including a complete response lasting more than 15 months.
Promising Business Development and Collaborations
Ongoing business development discussions have been positive, with pelareorep showing potential in breast, pancreatic, and anal cancers. Collaborations with GCAR and PanCAN continue to progress, with a $5 million grant from PanCAN funding goblet cohort five.
Robust Financial Management
As of December 31, 2024, the company reported $15.9 million in cash and cash equivalents, with net cash used in operating activities slightly reduced from the previous year.
Lowlights
Net Loss Increase
Net loss for the fourth quarter of 2024 was $8 million, compared to $3.9 million for the same period in 2023, marking an increase in net loss.
CEO Transition
The company is in the process of searching for a new permanent CEO following the departure of Dr. Matthew Coffey, who stepped down to focus on his recovery.
Uncertainties in Regulatory Pathways
Discussions with regulators and key opinion leaders are ongoing, with uncertainties around the timing and costs of launching registration-enabling studies in breast cancer.
Company Guidance
The recent conference call from Oncolytics Biotech Inc. provided a comprehensive update on the company's 2024 performance and future guidance. The call highlighted significant progress in the development of pelareorep (PELA), particularly its potential in HR-positive HER2-negative metastatic breast cancer, with plans to initiate a Phase 2 study involving 180 patients. The trial aims to establish a progression-free survival (PFS) endpoint within two years, supporting an accelerated approval submission. The BRACELET-1 study showed a clinically meaningful advantage of more than 12 months in overall survival for patients on PELA combination therapy compared to monotherapy. The call emphasized the promising initial safety and efficacy data from the goblet study in pancreatic and anal cancers, including a 33% objective response rate in relapsed anal cancer and financial backing from PanCAN with a $5 million grant. Financially, the company recorded a net loss of $31.7 million in 2024, with cash and equivalents at $15.9 million by year-end. Looking forward, the company is actively searching for a new CEO and is optimistic about PELA's broad potential across breast, pancreatic, and anal cancers, estimating a $2.4 billion market opportunity in the U.S. and Europe by 2033.Oncolytics Biotech Corporate Events
Oncolytics Biotech Advances Pancreatic Cancer Treatment with Regulatory Approval
Jan 15, 2025
Oncolytics Biotech has received regulatory approval from Germany’s Paul-Ehrlich-Institute to proceed with the full enrollment of Cohort 5 in their GOBLET study, which evaluates the combination of pelareorep and mFOLFIRINOX, with or without atezolizumab, for pancreatic ductal adenocarcinoma patients. This approval follows a favorable safety review, and early safety data will be presented at the upcoming 2025 ASCO Symposium. The progression of this cohort could potentially expand treatment options for metastatic pancreatic cancer patients, significantly impacting Oncolytics’ position in the oncology market.
Oncolytics Biotech Reports Promising Cancer Study Results
Dec 23, 2024
Oncolytics Biotech has achieved significant clinical advancements in 2024, with promising results in metastatic breast and gastrointestinal cancers, setting the stage for potential regulatory approvals. The company’s strategic collaborations and ongoing studies aim to enhance treatment options, creating new opportunities for investors and stakeholders in 2025.
Oncolytics Biotech Unveils Promising Cancer Therapy Results
Dec 18, 2024
Oncolytics Biotech is set to showcase promising results of their immunotherapy drug, pelareorep, in treating hard-to-treat gastrointestinal cancers at the upcoming ASCO GI Symposium. The data highlights pelareorep’s ability to enhance the effectiveness of existing cancer treatments, potentially improving patient outcomes in pancreatic and anal cancers.
Oncolytics Biotech Progresses with GOBLET Cancer Trial
Dec 3, 2024
Oncolytics Biotech has announced the completion of the initial safety phase enrollment for the GOBLET trial’s new pancreatic cancer cohort, which aims to enhance treatment options with their flagship drug pelareorep. The trial, backed by a $5 million award from the Pancreatic Cancer Action Network, seeks to evaluate the drug’s efficacy in combination with other treatments, potentially offering new hope for pancreatic cancer patients.
Oncolytics Biotech Reports Promising Cancer Treatment Results
Nov 12, 2024
Oncolytics Biotech reported positive results for its pelareorep and paclitaxel combination, showing significant improvements in survival rates for metastatic breast cancer patients. The company, with a solid cash position, plans to advance to a registration-enabling study. Oncolytics’ financial stability and promising clinical data suggest potential growth in the oncology sector.
Oncolytics Biotech Announces Q3 Results Conference
Nov 11, 2024
Oncolytics Biotech is set to discuss its third-quarter financial results and recent operational achievements in an upcoming conference call. The company, known for its promising cancer immunotherapy, pelareorep, is advancing towards key registrational studies after receiving fast-track designations from the FDA.
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.